JP6026507B2 - 電子ビーム照射後のポリマー医療機器のコンディショニング - Google Patents
電子ビーム照射後のポリマー医療機器のコンディショニング Download PDFInfo
- Publication number
- JP6026507B2 JP6026507B2 JP2014508336A JP2014508336A JP6026507B2 JP 6026507 B2 JP6026507 B2 JP 6026507B2 JP 2014508336 A JP2014508336 A JP 2014508336A JP 2014508336 A JP2014508336 A JP 2014508336A JP 6026507 B2 JP6026507 B2 JP 6026507B2
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- temperature
- stent
- exposure
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920000642 polymer Polymers 0.000 title claims description 308
- 238000010894 electron beam technology Methods 0.000 title claims description 31
- 230000003750 conditioning effect Effects 0.000 title description 72
- 230000001954 sterilising effect Effects 0.000 claims description 97
- 238000004659 sterilization and disinfection Methods 0.000 claims description 95
- 238000000034 method Methods 0.000 claims description 70
- 238000002788 crimping Methods 0.000 claims description 55
- 229920001432 poly(L-lactide) Polymers 0.000 claims description 53
- 230000009477 glass transition Effects 0.000 claims description 34
- 230000005855 radiation Effects 0.000 claims description 23
- 229920001244 Poly(D,L-lactide) Polymers 0.000 claims description 9
- -1 polymandelide Polymers 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 3
- 229920000954 Polyglycolide Polymers 0.000 claims description 3
- 150000003254 radicals Chemical class 0.000 description 36
- 239000000047 product Substances 0.000 description 31
- 239000000463 material Substances 0.000 description 30
- 230000035882 stress Effects 0.000 description 28
- 238000010438 heat treatment Methods 0.000 description 26
- 230000007423 decrease Effects 0.000 description 24
- 230000008859 change Effects 0.000 description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 13
- 239000011248 coating agent Substances 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 238000011282 treatment Methods 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- JJTUDXZGHPGLLC-IMJSIDKUSA-N 4511-42-6 Chemical group C[C@@H]1OC(=O)[C@H](C)OC1=O JJTUDXZGHPGLLC-IMJSIDKUSA-N 0.000 description 8
- 230000001143 conditioned effect Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000036760 body temperature Effects 0.000 description 7
- 238000003860 storage Methods 0.000 description 7
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 6
- 239000005977 Ethylene Substances 0.000 description 6
- 206010073306 Exposure to radiation Diseases 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000001816 cooling Methods 0.000 description 5
- 230000001419 dependent effect Effects 0.000 description 5
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- 238000002844 melting Methods 0.000 description 5
- 230000008018 melting Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 208000031481 Pathologic Constriction Diseases 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 229920001400 block copolymer Polymers 0.000 description 4
- 229920001577 copolymer Polymers 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000037803 restenosis Diseases 0.000 description 4
- 230000036262 stenosis Effects 0.000 description 4
- 208000037804 stenosis Diseases 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical group [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 238000002399 angioplasty Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 229910052786 argon Inorganic materials 0.000 description 3
- 229920000229 biodegradable polyester Polymers 0.000 description 3
- 239000004622 biodegradable polyester Substances 0.000 description 3
- 229920002988 biodegradable polymer Polymers 0.000 description 3
- 239000004621 biodegradable polymer Substances 0.000 description 3
- 238000012668 chain scission Methods 0.000 description 3
- 239000008199 coating composition Substances 0.000 description 3
- 230000001351 cycling effect Effects 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 238000012377 drug delivery Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229960005167 everolimus Drugs 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 238000003698 laser cutting Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 229920001684 low density polyethylene Polymers 0.000 description 3
- 239000004702 low-density polyethylene Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000005507 spraying Methods 0.000 description 3
- 238000011287 therapeutic dose Methods 0.000 description 3
- 239000003190 viscoelastic substance Substances 0.000 description 3
- 230000036642 wellbeing Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229920005603 alternating copolymer Polymers 0.000 description 2
- 229920006125 amorphous polymer Polymers 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 238000001815 biotherapy Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 239000013013 elastic material Substances 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 2
- 239000000622 polydioxanone Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920005594 polymer fiber Polymers 0.000 description 2
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 2
- 229920005604 random copolymer Polymers 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 229920006126 semicrystalline polymer Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000011345 viscous material Substances 0.000 description 2
- 238000003466 welding Methods 0.000 description 2
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 description 2
- 229950009819 zotarolimus Drugs 0.000 description 2
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- ZMKVBUOZONDYBW-UHFFFAOYSA-N 1,6-dioxecane-2,5-dione Chemical compound O=C1CCC(=O)OCCCCO1 ZMKVBUOZONDYBW-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000004435 EPR spectroscopy Methods 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000012669 compression test Methods 0.000 description 1
- 229920013750 conditioning polymer Polymers 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000001723 curing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- REQPQFUJGGOFQL-UHFFFAOYSA-N dimethylcarbamothioyl n,n-dimethylcarbamodithioate Chemical compound CN(C)C(=S)SC(=S)N(C)C REQPQFUJGGOFQL-UHFFFAOYSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000005530 etching Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 238000001746 injection moulding Methods 0.000 description 1
- 238000010884 ion-beam technique Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 229940127554 medical product Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000009864 tensile test Methods 0.000 description 1
- 229920001897 terpolymer Polymers 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
- PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C71/00—After-treatment of articles without altering their shape; Apparatus therefor
- B29C71/02—Thermal after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
- A61L2/0029—Radiation
- A61L2/007—Particle radiation, e.g. electron-beam, alpha or beta radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
- A61L2/087—Particle radiation, e.g. electron-beam, alpha or beta radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
- B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/08—Heat treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
- C08J7/12—Chemical modification
- C08J7/123—Treatment by wave energy or particle radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
- A61F2002/91558—Adjacent bands being connected to each other connected peak to peak
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
- A61F2002/91583—Adjacent bands being connected to each other by a bridge, whereby at least one of its ends is connected along the length of a strut between two consecutive apices within a band
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2210/00—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2210/0004—Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2240/001—Designing or manufacturing processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
- A61L2/08—Radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
- A61L2202/20—Targets to be treated
- A61L2202/24—Medical instruments, e.g. endoscopes, catheters, sharps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C35/00—Heating, cooling or curing, e.g. crosslinking or vulcanising; Apparatus therefor
- B29C35/02—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould
- B29C35/08—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould by wave energy or particle radiation
- B29C35/0866—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould by wave energy or particle radiation using particle radiation
- B29C2035/0877—Heating or curing, e.g. crosslinking or vulcanizing during moulding, e.g. in a mould by wave energy or particle radiation using particle radiation using electron radiation, e.g. beta-rays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
- B29C71/00—After-treatment of articles without altering their shape; Apparatus therefor
- B29C71/02—Thermal after-treatment
- B29C2071/022—Annealing
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
- B29L2031/00—Other particular articles
- B29L2031/753—Medical equipment; Accessories therefor
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
- C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Thermal Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Surgery (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Optics & Photonics (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Materials For Medical Uses (AREA)
Description
本願は、2010年8月20日に出願された同時係属の米国特許出願第12/860,681号の一部継続出願であり、2010年4月21日に出願された同時係属の米国特許出願第12/764,803号の一部継続出願でもある。全ての図面を含むこれら明細書全体を引用して本明細書に援用する。
本発明は、生体吸収性ポリマーからステントを製作する方法に関する。
下記表1に上記ポリマーの内の幾つかのTgを示す。
周囲温度は、20℃〜25℃の間の任意の温度に相当する。
以下に説明する実施例は、説明のみを目的とし、本発明の制限を意図していない。以下の実施例は本発明の理解を深めるための助けとなるが、言うまでもなく、本発明は、特定の実施例に限定されない。パラメータおよびデータが本発明の実施の形態の範囲を限定すると解釈すべきではない。
以下の実施例では、放射線滅菌後に周囲温度を超える温度に暴露されるポリマー製ステントのフリーラジカル濃度への効果を説明する。本研究で使用されたステントは、PLLAで作製されたスキャフォールドである。
ポリマーステントはポリ(L−ラクチド)(PLLA)で製造された。ポリマーチューブは、Boehringer Ingelheim社のRESOMAR(登録商標)L210S、ポリ(L−ラクチド)(PLLA)のポリマーチューブ押出成形により作製され、径方向拡張が約400%〜約500%以内、軸方向拡張が約20%〜約120%以内となるようにポリマーチューブを2軸拡張させ、チューブにステントパターンをレーザーカッティングしてステントを形成した。続いて、放射線不透過のマーカーをステントに配置し、ポリマーおよび薬品(PDLLAおよびエベロリムス)を含む薬品送達被膜を塗布した。ステントは、約40℃〜50℃の温度でバルーンカテーテルにクリンピングされた。ステントは、ミシガン州GrandRapidsにあるOliver−Tolas社製のフォイルでできた袋(MARVELSEALTM(商標)360−ナイロン/アルミニウム/LDPE)内にパッケージ化された。パッケージはアルゴン雰囲気で封止された。本研究のステントは31kGyの放射線量をもつ電子ビーム照射により滅菌された。
ポリマーステントは、ポリ(L−ラクチド)(PLLA)で製造され、実施例2の説明と同様に被覆、クリンピングおよび滅菌された。径方向強度は、回復不能な変形が観察された時の圧力として判定された。その試験には、速度0.5mm/secでMSI RX550(商標)径方向力試験装置を利用し、試験は37℃行った。ポリマーステントの径方向強度は滅菌後の時間関数として測定された。ステントは、滅菌時から測定時まで室温(25±3℃)に維持された。図6に示すように、径方向強度は滅菌後の時間関数として減少し、約60日で「疑似定常状態」、「疑似平衡状態」または安定期の値に達する。
[第1の局面]
ポリマーステントをコンディショニングするための方法であって:
ポリマースキャフォールドを有するポリマーステントを、ある期間、30℃に等しい、30℃にほぼ等しい、または30℃を超える温度で、かつ、最大で前記ポリマースキャフォールドのガラス転移温度より約15℃低い温度に暴露するステップを含み、前記期間は少なくとも8時間であり;
前記ポリマーステントは、前記暴露前に送達機器へクリンピングされ、パッケージ化され、および滅菌され;
前記ポリマースキャフォールドは、前記ガラス転移温度より高い温度で応力を加えて変形させたポリマー成形品から形成され;
前記ポリマー成形品の前記ガラス転移温度は、25℃を超え;
前記暴露温度は、±3℃以内に管理される;
コンディショニング方法。
[第2の局面]
前記ポリマー成形品は、ポリマーチューブであり、
応力を加えた前記変形は、前記ポリマーチューブの径方向への拡張を含む、
第1の局面の方法。
[第3の局面]
前記ポリマースキャフォールドは、ポリ(L−ラクチド)、ポリマンデリド、ポリ(DL−ラクチド)、ポリグリコリド、ポリ(L−ラクチド−co−グリコリド)、および全ての比率でのそれら全ての組合せからなるグループから選定されるポリマーを含む、
第1の局面の方法。
[第4の局面]
前記暴露温度は、最大で前記ポリマースキャフォールドの前記ガラス転移温度より20℃低い、
第1の局面の方法。
[第5の局面]
前記暴露期間は、約8時間〜約20日であり、
前記暴露温度は、約32℃〜約40℃である、
第1の局面の方法。
[第6の局面]
前記暴露期間は、約1日〜約10日である、
第5の局面の方法。
[第7の局面]
前記暴露期間は、約2日〜約6日である、
第6の局面の方法。
[第8の局面]
前記暴露温度は、約35℃〜約40℃の範囲である、
第7の局面の方法。
[第9の局面]
前記ポリマースキャフォールドを有する前記ポリマーステントを、ある期間、35℃に等しい、または35℃を超える温度で、かつ前記ポリマースキャフォールドの前記ガラス転移温度より最大で約10℃高い温度に暴露するステップをさらに含み、
前記期間は、約4時間〜約10日間の範囲であり、前記ポリマーステントが送達機器にクリンピングされた後であって、前記ポリマーステントが滅菌される前に行い、
前記クリンピング後かつ前記滅菌前の前記暴露温度を±3℃以内に管理する、
第1の局面の方法。
[第10の局面]
前記クリンピング後かつ前記滅菌前の前記暴露期間は、約16時間〜約48時間であり、
前記クリンピング後かつ前記滅菌前の前記暴露温度は、約45℃〜約65℃である、
第9の局面の方法。
[第11の局面]
前記クリンピング後かつ前記滅菌前の前記暴露期間は、約16時間〜約32時間であり、
前記クリンピング後かつ前記滅菌前の前記暴露温度は、約50℃〜約65℃である、
第10の局面の方法。
[第12の局面]
前記ポリマーステントは、約40℃〜約50℃の範囲の温度で送達機器へクリンピングされる、
第1の局面の方法。
[第13の局面]
前記滅菌後の曝露温度は、約33℃かつ37℃以下であり、
前記滅菌後の曝露期間は、約32時間〜約84時間の範囲である、
第12の局面の方法。
[第14の局面]
前記ポリマーステントは、送達機器上に約48℃の範囲の温度でクリンピングされ、
前記滅菌後の暴露温度は、約35℃であり、
前記滅菌後の暴露期間は、約48時間〜約72時間の範囲である、
第13の局面の方法。
[第15の局面]
ポリマーステントをコンディショニングする方法であって:
基本的にポリ(L−ラクチド)を含むポリマースキャフォールドを有するポリマーステントを、ある期間、30℃に等しい、30℃にほぼ等しい、または30℃を超える温度で、かつ約55℃以下の温度に暴露することを含み、前記期間は少なくとも8時間であり;
前記ポリマーステントは、前記暴露前に、送達機器上にクリンピングされ、パッケージ化され、および滅菌され;
前記ポリマースキャフォールドは、応力が加えられて変形した、基本的にポリ(L−ラクチド)を含むポリマーチューブから形成され、前記変形は、前記ポリマーチューブのガラス転移温度より高い温度で前記ポリマーチューブの径方向への拡張を含み;
前記暴露温度を±3℃以内に管理する、
コンディショニング方法。
[第16の局面]
前記暴露期間は、約8時間〜約20日であり、
前記暴露温度は、約32℃〜約40℃である、
第15の局面の方法。
[第17の局面]
前記暴露期間は、約1日〜約10日である、
第16の局面の方法。
[第18の局面]
前記暴露期間は、約2日〜約6日であり、
前記暴露温度は、約35℃〜約40℃である、
第17の局面の方法。
[第19の局面]
前記ポリマースキャフォールドを有する前記ポリマーステントを、ある期間、35℃に等しい、または35℃を超える温度で、かつ約70℃以下の温度に暴露することをさらに含み、前記期間は、前記ポリマーステントを送達機器にクリンピングした後で、前記ポリマーステントを滅菌する前の約4時間〜約6日間であり;
前記クリンピング後かつ前記滅菌前の前記暴露温度は、±3℃以内に管理される、
第15の局面の方法。
[第20の局面]
前記クリンピング後かつ前記滅菌前の前記暴露期間は、約16時間〜約48時間であり、
前記クリンピング後で前記滅菌前の前記暴露温度は、約45℃〜約65℃である、
第19の局面の方法。
[第21の局面]
前記クリンピング後かつ前記滅菌前の前記暴露期間は、約16時間〜約32時間であり、
前記クリンピング後で前記滅菌前の前記暴露温度は、約50℃〜約65℃である、
第20の局面の方法。
[第22の局面]
前記ポリマーステントが、約45℃〜約50℃の温度で送達機器にクリンピングされる、
第15の局面の方法。
[第23の局面]
前記滅菌後の暴露温度は、約33℃から約37℃以下の範囲であり、
前記滅菌後の暴露期間は、約32時間〜約84時間の範囲である、
第22の局面の方法。
[第24の局面]
前記ポリマーステントは、約48℃の温度で送達機器にクリンピングされ、
前記滅菌後の暴露温度は、約35℃であり、
前記滅菌後の暴露期間は、約48時間〜約72時間の範囲である、
第23の局面の方法。
[第25の局面]
ポリマーステントをコンディショニングする方法であって:
ポリマースキャフォールドを有するポリマーステントを、径方向強度が少なくとも10%だけ低下するように、ある期間、30℃に等しい、30℃にほぼ等しい、または30℃を超える温度で、かつ約55℃以下の温度に暴露するステップを含み;
前記期間は、少なくとも30分間であり;
前記ポリマーステントは、前記暴露前に送達機器上にクリンピングされ、パッケージ化され、および滅菌され;
前記ポリマースキャフォールドは、応力が加えられることにより変形しているポリマーチューブから形成され、前記変形は、前記ポリマーチューブのガラス転移温度を超える温度での前記ポリマーチューブの径方向への拡張を含み;
前記暴露温度は、±3℃以内に管理される、
コンディショニング方法。
Claims (14)
- ポリマーステントを調整して製造する方法であって:
ポリマースキャフォールドを有するポリマーステントを、ある期間、30℃に等しい、30℃にほぼ等しい、または30℃を超える温度で、かつ、最大で前記ポリマースキャフォールドのガラス転移温度より15℃低い温度に暴露する第1の曝露ステップを含み、前記期間は少なくとも8時間であり;
前記ポリマーステントは、前記第1の暴露前に送達機器へクリンピングされ、パッケージ化され、および、電子ビーム放射線で滅菌され;
前記ポリマースキャフォールドは、前記ガラス転移温度より高い温度で応力を加えて変形させたポリマー成形品から形成され;
前記ポリマー成形品の前記ガラス転移温度は、25℃を超え;
前記第1の暴露の温度は、±3℃以内に管理される;
ポリマーステントの製造方法。 - 前記ポリマー成形品は、ポリマーチューブであり、
応力を加えた前記変形は、前記ポリマーチューブの径方向への拡張を含む、
請求項1の方法。 - 前記ポリマースキャフォールドは、ポリ(L−ラクチド)、ポリマンデリド、ポリ(DL−ラクチド)、ポリグリコリド、ポリ(L−ラクチド−co−グリコリド)、および全ての比率でのそれら全ての組合せからなるグループから選定されるポリマーを含む、
請求項1または請求項2の方法。 - 前記第1の暴露の温度は、最大で前記ポリマースキャフォールドの前記ガラス転移温度より20℃低い、
請求項1〜請求項3のいずれか1項の方法。 - 前記第1の暴露の期間は、8時間〜20日であり、
前記第1の暴露の温度は、32℃〜40℃である、
請求項1〜請求項4のいずれか1項の方法。 - 前記第1の暴露の期間は、1日〜10日である、
請求項5の方法。 - 前記第1の暴露の期間は、2日〜6日である、
請求項6の方法。 - 前記第1の暴露の温度は、35℃〜40℃の範囲である、
請求項7の方法。 - 前記ポリマースキャフォールドを有する前記ポリマーステントを、ある期間、35℃に等しい、または35℃を超える温度で、かつ前記ポリマースキャフォールドの前記ガラス転移温度より最大で10℃高い温度に暴露する第2の曝露ステップをさらに含み、
前記第2の曝露の期間は、4時間〜10日間の範囲であり、前記ポリマーステントが送達機器にクリンピングされた後であって、前記ポリマーステントが滅菌される前に行い、
前記クリンピング後かつ前記滅菌前の前記第2の暴露の温度を±3℃以内に管理する、
請求項1〜請求項4のいずれか1項の方法。 - 前記クリンピング後かつ前記滅菌前の前記第2の暴露の期間は、16時間〜48時間であり、
前記クリンピング後かつ前記滅菌前の前記第2の暴露の温度は、45℃〜65℃である、
請求項9の方法。 - 前記クリンピング後かつ前記滅菌前の前記第2の暴露の期間は、16時間〜32時間であり、
前記クリンピング後かつ前記滅菌前の前記第2の暴露の温度は、50℃〜65℃である、
請求項10の方法。 - 前記ポリマーステントは、40℃〜50℃の範囲の温度で送達機器へクリンピングされる、
請求項1〜請求項4、請求項9〜請求項11のいずれか1項の方法。 - 前記滅菌後の前記第1の曝露の温度は、33℃〜37℃であり、
前記滅菌後の前記第1の曝露の期間は、32時間〜84時間の範囲である、
請求項12の方法。 - 前記ポリマーステントは、送達機器上に48℃の温度でクリンピングされ、
前記滅菌後の前記第1の暴露の温度は、35℃であり、
前記滅菌後の前記第1の暴露の期間は、48時間〜72時間の範囲である、
請求項13の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/093,755 | 2011-04-25 | ||
US13/093,755 US8613880B2 (en) | 2010-04-21 | 2011-04-25 | Post electron beam conditioning of polymeric medical devices |
PCT/US2011/057932 WO2012148452A1 (en) | 2011-04-25 | 2011-10-26 | Post electron beam conditioning of polymeric medical devices |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014516641A JP2014516641A (ja) | 2014-07-17 |
JP2014516641A5 JP2014516641A5 (ja) | 2014-12-11 |
JP6026507B2 true JP6026507B2 (ja) | 2016-11-16 |
Family
ID=44999890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014508336A Expired - Fee Related JP6026507B2 (ja) | 2011-04-25 | 2011-10-26 | 電子ビーム照射後のポリマー医療機器のコンディショニング |
Country Status (5)
Country | Link |
---|---|
US (3) | US8613880B2 (ja) |
EP (1) | EP2701894B1 (ja) |
JP (1) | JP6026507B2 (ja) |
CN (1) | CN103619568B (ja) |
WO (1) | WO2012148452A1 (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8486135B2 (en) | 2006-06-01 | 2013-07-16 | Abbott Cardiovascular Systems Inc. | Implantable medical devices fabricated from branched polymers |
US8814930B2 (en) | 2007-01-19 | 2014-08-26 | Elixir Medical Corporation | Biodegradable endoprosthesis and methods for their fabrication |
US10898620B2 (en) | 2008-06-20 | 2021-01-26 | Razmodics Llc | Composite stent having multi-axial flexibility and method of manufacture thereof |
US8206635B2 (en) | 2008-06-20 | 2012-06-26 | Amaranth Medical Pte. | Stent fabrication via tubular casting processes |
US8206636B2 (en) | 2008-06-20 | 2012-06-26 | Amaranth Medical Pte. | Stent fabrication via tubular casting processes |
US8765040B2 (en) | 2008-08-11 | 2014-07-01 | Abbott Cardiovascular Systems Inc. | Medical device fabrication process including strain induced crystallization with enhanced crystallization |
US8372332B2 (en) * | 2008-08-11 | 2013-02-12 | Abbott Cardiovascular Systems Inc. | Fabricating an implantable medical device from an amorphous or very low crystallinity polymer construct |
US8834776B2 (en) * | 2011-05-10 | 2014-09-16 | Abbott Cardiovascular Systems Inc. | Control of degradation profile of bioabsorbable poly(l-lactide) scaffold |
US10518003B2 (en) * | 2014-07-07 | 2019-12-31 | Meril Life Sciences Pvt. Ltd. | Method to manufacture thin strut stent from bioabsorbable polymer with high fatigue and radial strength |
US9855156B2 (en) * | 2014-08-15 | 2018-01-02 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
US9730819B2 (en) | 2014-08-15 | 2017-08-15 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
US9480588B2 (en) | 2014-08-15 | 2016-11-01 | Elixir Medical Corporation | Biodegradable endoprostheses and methods of their fabrication |
ES2873887T3 (es) | 2016-05-16 | 2021-11-04 | Elixir Medical Corp | Liberación de stent |
US11622872B2 (en) | 2016-05-16 | 2023-04-11 | Elixir Medical Corporation | Uncaging stent |
US11534508B2 (en) | 2017-02-08 | 2022-12-27 | Mitsubishi Gas Chemical Company, Inc. | Method for producing sterilized oxygen-absorbing multilayer body |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6274364A (ja) | 1985-09-27 | 1987-04-06 | 株式会社 ニツシヨ− | 医療用具 |
US5414049A (en) | 1993-06-01 | 1995-05-09 | Howmedica Inc. | Non-oxidizing polymeric medical implant |
JP3787993B2 (ja) | 1997-10-27 | 2006-06-21 | 株式会社Nhvコーポレーション | 電子線照射装置 |
JP3785473B2 (ja) * | 1998-06-22 | 2006-06-14 | 日本ゼオン株式会社 | 放射線滅菌法および滅菌した成形品 |
JP2000334028A (ja) | 1999-05-26 | 2000-12-05 | Ishikawajima Harima Heavy Ind Co Ltd | 医療用品の電子線による滅菌方法 |
US7807211B2 (en) | 1999-09-03 | 2010-10-05 | Advanced Cardiovascular Systems, Inc. | Thermal treatment of an implantable medical device |
US7150853B2 (en) | 2001-11-01 | 2006-12-19 | Advanced Cardiovascular Systems, Inc. | Method of sterilizing a medical device |
JP2007512908A (ja) * | 2003-12-01 | 2007-05-24 | アドヴァンスド カーディオヴァスキュラー システムズ, インコーポレイテッド | 温度調整式圧着法 |
US8747878B2 (en) | 2006-04-28 | 2014-06-10 | Advanced Cardiovascular Systems, Inc. | Method of fabricating an implantable medical device by controlling crystalline structure |
US7971333B2 (en) | 2006-05-30 | 2011-07-05 | Advanced Cardiovascular Systems, Inc. | Manufacturing process for polymetric stents |
US8012402B2 (en) | 2008-08-04 | 2011-09-06 | Abbott Cardiovascular Systems Inc. | Tube expansion process for semicrystalline polymers to maximize fracture toughness |
US7694813B2 (en) | 2005-09-16 | 2010-04-13 | Poly-Med, Inc. | Package components for radiochemical sterilization |
WO2006034157A2 (en) | 2004-09-17 | 2006-03-30 | Poly-Med, Inc. | Package components for radiochemical sterilization |
US7297758B2 (en) | 2005-08-02 | 2007-11-20 | Advanced Cardiovascular Systems, Inc. | Method for extending shelf-life of constructs of semi-crystallizable polymers |
US20070132155A1 (en) | 2005-12-13 | 2007-06-14 | Robert Burgermeister | Polymeric stent having modified molecular structures in selected regions of the hoops and method for increasing elongation at break |
US20080169582A1 (en) | 2006-10-23 | 2008-07-17 | Vipul Bhupendra Dave | Method and apparatus for making polymeric drug delivery devices having differing morphological structures |
US20080103584A1 (en) * | 2006-10-25 | 2008-05-01 | Biosensors International Group | Temporal Intraluminal Stent, Methods of Making and Using |
US8182890B2 (en) | 2007-01-19 | 2012-05-22 | Elixir Medical Corporation | Biodegradable endoprostheses and methods for their fabrication |
CN100556376C (zh) * | 2007-10-09 | 2009-11-04 | 浙江铭众科技有限公司 | 胃肠吻合支架的制备方法 |
WO2009076350A1 (en) * | 2007-12-11 | 2009-06-18 | Abbott Cardiovascular Systems Inc. | Method of fabricating a stent from blow molded tubing |
WO2009103012A1 (en) * | 2008-02-14 | 2009-08-20 | Tengion, Inc. | Tissue engineering scaffolds |
US8394317B2 (en) | 2008-08-11 | 2013-03-12 | Abbott Cardiovascular Systems Inc. | Method of improving fracture toughness of implantable medical devices through annealing |
US20110066223A1 (en) * | 2009-09-14 | 2011-03-17 | Hossainy Syed F A | Bioabsorbable Stent With Time Dependent Structure And Properties |
US8715569B2 (en) * | 2010-08-20 | 2014-05-06 | Abbott Cardiovascular Systems Inc. | Post electron beam stabilization of polymeric medical devices |
-
2011
- 2011-04-25 US US13/093,755 patent/US8613880B2/en active Active
- 2011-10-26 JP JP2014508336A patent/JP6026507B2/ja not_active Expired - Fee Related
- 2011-10-26 WO PCT/US2011/057932 patent/WO2012148452A1/en active Application Filing
- 2011-10-26 CN CN201180071619.6A patent/CN103619568B/zh active Active
- 2011-10-26 EP EP11785185.7A patent/EP2701894B1/en not_active Not-in-force
-
2013
- 2013-12-23 US US14/139,740 patent/US9566723B2/en active Active
-
2017
- 2017-01-03 US US15/397,574 patent/US20170113424A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2701894A1 (en) | 2014-03-05 |
CN103619568B (zh) | 2016-03-09 |
CN103619568A (zh) | 2014-03-05 |
US20170113424A1 (en) | 2017-04-27 |
US9566723B2 (en) | 2017-02-14 |
JP2014516641A (ja) | 2014-07-17 |
US20110260358A1 (en) | 2011-10-27 |
US20140110885A1 (en) | 2014-04-24 |
WO2012148452A1 (en) | 2012-11-01 |
US8613880B2 (en) | 2013-12-24 |
EP2701894B1 (en) | 2017-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6026507B2 (ja) | 電子ビーム照射後のポリマー医療機器のコンディショニング | |
JP6421034B2 (ja) | 生体吸収性ポリ(l−ラクチド)スキャフォールドの分解プロファイルの管理 | |
US9655751B2 (en) | Kits including implantable medical devices and antioxidants | |
JP6375401B2 (ja) | 滅菌後のポリマーステントの分子量を安定化させる方法 | |
US8882825B2 (en) | Stents including poly(L-lactide) formulations that minimize molecular weight drop during processing | |
JP6183808B2 (ja) | ポリマー製医療用装具の電子線後安定化 | |
US20130032967A1 (en) | Cold ethylene oxide sterilization of a biodegradable polymeric stent | |
JP6339168B2 (ja) | 末梢動脈疾患のための薬剤送達機器 | |
WO2013043429A1 (en) | Cold ethylene oxide sterilization of a biodegradable polymeric stent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141024 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141024 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150901 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160301 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160530 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160920 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161012 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6026507 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |